Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

• Revenue in USD (TTM)203.45m
• Net income in USD-348.96m
• Incorporated2008
• Employees380.00

• Location
  Travere Therapeutics Inc3611 Valley Centre Dr, Suite 300SAN DIEGO 92130United StatesUSA
• Phone+1 (760) 260-8600
• Fax+1 (302) 645-1280
• Websitehttps://travere.com/